Tesamorelin Injection Sites Best Locations — Expert Guide
Research from multiple Phase 3 trials examining tesamorelin (EGRIFTA) for HIV-associated lipodystrophy consistently administered injections into the abdominal subcutaneous tissue. Not because convenience dictated it, but because that's where visceral adipose tissue (VAT) accumulation occurs and where the GH-releasing mechanism achieves maximum therapeutic effect. The distinction matters: tesamorelin works by stimulating endogenous growth hormone secretion from the anterior pituitary, which then acts systemically on VAT through lipolytic pathways. Injection site selection directly impacts absorption kinetics, patient comfort, and adherence across weeks or months of daily administration.
Our team has worked with researchers studying peptide administration protocols across multiple compound classes. The gap between optimal injection technique and common practice shows up most clearly in subcutaneous peptides targeting specific fat depots. Tesamorelin being the clearest example.
What are the best locations for tesamorelin injections?
The abdomen (specifically the periumbilical region excluding a 2-inch radius around the navel itself) represents the optimal primary site for tesamorelin subcutaneous injection based on clinical trial protocols and absorption data. Alternative rotation sites include the anterior thigh and outer upper arm, though abdominal administration remains standard due to consistent subcutaneous tissue thickness and proximity to the VAT depot tesamorelin targets. Rotate injection points within each anatomical zone by at least one inch from the previous site to prevent lipohypertrophy and maintain absorption consistency.
Here's what's rarely explained in product literature: tesamorelin doesn't directly target injection-site fat. It triggers systemic GH release that preferentially acts on visceral adipose tissue regardless of where you inject. But absorption rate, injection comfort, and long-term tissue integrity all depend heavily on correct anatomical site selection and rotation discipline. This guide covers the four FDA-recognised injection zones for subcutaneous peptides, the anatomical reasoning behind prioritising abdominal sites for tesamorelin specifically, and the rotation protocols that prevent the tissue damage we see in patients who stick to the same 2-inch patch for months.
Optimal Anatomical Zones for Subcutaneous Tesamorelin Administration
The abdomen provides the most consistent subcutaneous fat layer depth (10–20mm in most adults) and the fastest absorption kinetics for peptides compared to limb sites. For tesamorelin specifically, abdominal injection sites offer three advantages: reliable subcutaneous tissue thickness across a large surface area allowing extensive rotation, higher subcutaneous blood flow than limb sites (enhancing peptide absorption), and patient accessibility for self-administration without assistance. The FDA-approved prescribing information for EGRIFTA specifies abdominal subcutaneous tissue as the primary injection site, validated through the original Phase 2 and Phase 3 efficacy trials.
Within the abdominal zone, target the periumbilical region. The area surrounding the navel. While maintaining a minimum 2-inch exclusion radius from the umbilicus itself. This exclusion prevents injection into the relatively avascular central umbilical scar tissue and reduces discomfort. Divide the eligible abdominal area into four quadrants (upper right, upper left, lower right, lower left) and rotate systematically between them. Each injection within a quadrant should be spaced at least one inch from the previous injection site to allow tissue recovery and prevent lipohypertrophy. The localised fat accumulation or tissue thickening that impairs absorption and causes visible skin changes.
Alternative sites include the anterior thigh (front and outer thigh, avoiding the inner thigh and areas within 2 inches of the knee) and the outer upper arm (posterior-lateral deltoid region). These sites work when abdominal tissue is compromised, scarred, or temporarily unsuitable. Thigh injections provide similar subcutaneous depth but slightly slower absorption due to lower regional blood flow. Upper arm sites are the least preferred for self-administration due to access difficulty without assistance and smaller usable surface area limiting rotation options.
Rotation Protocols and Tissue Preservation Strategies
Systematic site rotation isn't optional. It's what separates patients who maintain consistent absorption across months of daily administration from those who develop injection-site complications requiring therapy interruption. Lipohypertrophy develops when the same subcutaneous location receives repeated injections within a 4-week window, causing localised inflammatory responses, collagen deposition, and adipocyte hypertrophy. The resulting tissue changes reduce peptide absorption by 20–30% compared to healthy subcutaneous tissue, creating unpredictable pharmacokinetics even when dosing remains constant.
The standard rotation protocol for daily tesamorelin administration involves dividing your primary injection zone (abdomen) into at least 8 discrete sites, each separated by a minimum of one inch in all directions. Number these sites mentally or mark them on a body diagram, then cycle through them sequentially. Site 1 on day 1, site 2 on day 2, and so forth. With 8 sites, each location receives an injection once every 8 days, allowing 7 days of tissue recovery between uses. This schedule prevents lipohypertrophy formation and maintains normal subcutaneous architecture.
Inspect each potential injection site before use. Skip any area showing redness, swelling, bruising, or palpable tissue thickening. These signs indicate incomplete healing from a previous injection or early lipohypertrophy formation. Move to the next site in your rotation sequence rather than forcing an injection into compromised tissue. Our experience across peptide therapy protocols shows that patients who visually inspect and palpate sites before each injection catch tissue changes early, while those who inject without checking often don't notice lipohypertrophy until absorption becomes noticeably impaired.
Injection Depth, Needle Selection, and Technical Execution
Tesamorelin requires subcutaneous injection. Not intramuscular, not intradermal. The subcutaneous layer sits between the dermis (skin) and muscle fascia, typically 4–10mm deep depending on body composition and anatomical location. Needle length and injection angle determine whether you hit this target consistently. The FDA-approved reconstituted tesamorelin formulation uses a 1mL syringe with a 27-gauge, 0.5-inch needle. Short enough to remain subcutaneous in most patients when inserted at a 45-degree angle with a pinched skin fold.
Proper technique: pinch approximately one inch of skin and subcutaneous tissue between your thumb and forefinger at the chosen injection site, creating a raised fold. Insert the needle at a 45-degree angle to the skin surface. Not perpendicular. And advance until the needle is fully inserted. Release the pinched skin fold, then slowly depress the plunger over 5 seconds to inject the full dose. The slow injection rate reduces injection-site discomfort and allows the peptide solution to disperse through subcutaneous tissue rather than creating a localised bolus that causes pressure and pain.
Needle gauge matters for peptide viscosity and injection comfort. The 27-gauge needle specified for EGRIFTA represents a balance: thin enough to minimise skin trauma and discomfort, but wide enough to allow smooth flow of the reconstituted peptide solution without excessive plunger resistance. Using a thinner needle (higher gauge number like 30G or 31G) reduces discomfort slightly but increases injection time and the risk of needle bending during insertion. Using a thicker needle (lower gauge like 25G) speeds injection but causes more tissue trauma and higher rates of bruising. We've found that patients who stick with the FDA-specified 27G needle report the most consistent comfort and the fewest injection-site complications.
Tesamorelin Injection Sites Best Locations: Site Comparison
Abdomen (periumbilical, excluding 2-inch radius from navel)
10–20mm
Fastest (high regional blood flow)
Excellent (large surface area allows 8+ discrete sites)
Easy (full visual access and reach)
Primary site. Validated in Phase 3 trials, optimal for daily long-term use
Anterior/Outer Thigh
8–15mm
Moderate (lower blood flow than abdomen)
Good (sufficient surface area for 6–8 sites per thigh)
Easy (full visual access)
Secondary site. Use when abdominal tissue compromised or rotation needed
Outer Upper Arm (posterior-lateral deltoid)
6–12mm
Moderate to slow (lowest blood flow)
Limited (small usable area limits rotation to 4–5 sites)
Difficult (requires assistance or contortion for self-injection)
Tertiary site. Reserve for situations where abdomen and thighs unavailable
Key Takeaways
Tesamorelin absorption rate and injection comfort depend heavily on correct subcutaneous site selection. The abdomen provides the most consistent tissue depth and fastest absorption kinetics.
Rotate injection sites systematically within at least 8 discrete locations spaced one inch apart to prevent lipohypertrophy, which reduces peptide absorption by 20–30%.
The FDA-approved tesamorelin protocol specifies abdominal subcutaneous tissue using a 27-gauge, 0.5-inch needle inserted at 45 degrees into pinched skin.
Alternative injection sites include the anterior thigh and outer upper arm, though both offer smaller rotation areas and slightly slower absorption than abdominal administration.
Inspect each injection site visually and by palpation before use. Skip any area showing redness, swelling, or tissue thickening to maintain absorption consistency.
What If: Tesamorelin Injection Site Scenarios
What If I Develop a Bruise or Bleeding at an Injection Site?
Skip that specific location for at least 10 days and move to the next site in your rotation sequence. Minor bruising from capillary puncture is common and harmless. It indicates you hit a small blood vessel during needle insertion, not an injection technique error. Apply gentle pressure with clean gauze for 30 seconds immediately after injection to minimise bleeding and bruise formation. If bruising occurs frequently (more than once per week), review your injection angle and ensure you're releasing the pinched skin fold before depressing the plunger. Injecting into tented skin increases vascular trauma risk.
What If the Injection Site Develops a Hard Lump That Doesn't Resolve?
A persistent subcutaneous nodule lasting more than 5 days suggests early lipohypertrophy or sterile inflammatory response. Stop using that site entirely until the lump completely resolves. Which may take 3–4 weeks. And expand your rotation to include alternative anatomical zones like the thighs. Permanent avoidance of that specific point prevents progressive tissue damage. Contact your prescribing physician if the lump enlarges, becomes painful, or shows signs of infection (warmth, spreading redness, purulent drainage).
What If I Run Out of Suitable Abdominal Injection Sites?
Transition to anterior thigh sites following the same rotation protocol. Divide each thigh into 4 sites (8 total across both legs) and cycle through them systematically. Avoid the inner thigh (higher nerve density and discomfort) and areas within 2 inches of the knee. Thigh absorption is 10–15% slower than abdominal administration based on subcutaneous blood flow studies, but this difference doesn't meaningfully impact tesamorelin's efficacy when used consistently.
The Clinical Truth About Tesamorelin Injection Site Selection
Here's the honest answer: most injection-site complications with tesamorelin stem from inadequate rotation discipline, not poor technique. Patients who methodically rotate through 8 abdominal sites and skip compromised tissue maintain normal subcutaneous architecture and consistent absorption indefinitely. Patients who gravitate toward the same 2-inch zone because it's comfortable or convenient develop lipohypertrophy within 6–8 weeks, then struggle with unpredictable absorption that undermines therapeutic outcomes. The FDA's abdominal site recommendation isn't arbitrary. It's based on Phase 3 trial data showing optimal VAT reduction when tesamorelin is administered into the periumbilical region with disciplined rotation. Shortcuts here don't save time; they create problems that require therapy interruption to resolve.
For researchers working with tesamorelin or exploring other peptides like MK 677 for growth hormone pathway research, subcutaneous administration technique directly affects pharmacokinetic consistency across study cohorts. Real Peptides provides research-grade peptides synthesised to exact amino-acid specifications. The compounds we supply for laboratory investigation maintain the purity and consistency that clinical protocols demand.
The gap between knowing injection sites matter and actually implementing systematic rotation shows up in adherence data: patients who track their sites (via body diagram, rotation app, or numbered site sequence) maintain therapeutic absorption across months of daily tesamorelin use. Those who inject haphazardly develop tissue complications requiring site switching or therapy breaks. Both of which disrupt VAT reduction continuity. If you're three weeks into a tesamorelin protocol and still injecting into the same general area because it feels familiar, you're setting yourself up for lipohypertrophy that won't become apparent until absorption drops enough to notice reduced efficacy. Mark your sites now, rotate deliberately, and the subcutaneous tissue you preserve will maintain consistent peptide delivery across the entire treatment course.
Frequently Asked Questions
Inject tesamorelin into the periumbilical region — the area surrounding your navel — while maintaining at least a 2-inch exclusion radius from the umbilicus itself. Divide this zone into four quadrants (upper right, upper left, lower right, lower left) and rotate systematically between discrete injection points spaced at least one inch apart. The exclusion zone prevents injection into avascular scar tissue at the navel centre, which would impair absorption and cause discomfort.
No — daily injection into the same subcutaneous location causes lipohypertrophy within 6–8 weeks, reducing peptide absorption by 20–30% and creating visible tissue thickening. Rotate through at least 8 discrete sites with a minimum one-inch spacing between each point, cycling back to the first site only after 7 days of tissue recovery. This rotation discipline prevents injection-site complications and maintains consistent tesamorelin pharmacokinetics across months of daily use.
The FDA-approved EGRIFTA protocol specifies a 27-gauge, 0.5-inch needle for reconstituted tesamorelin administration. This gauge balances injection comfort (thin enough to minimise tissue trauma) with practical flow rate (wide enough to avoid excessive plunger resistance or needle bending). Using a 0.5-inch needle inserted at 45 degrees into pinched skin ensures subcutaneous placement rather than intramuscular injection in most body compositions.
Correct subcutaneous injection produces minimal immediate discomfort and no visible fluid leakage from the puncture site after needle withdrawal. If you see tesamorelin solution leaking back out after injection, you injected too shallow — into the dermis rather than subcutaneous tissue. If you experience sharp pain during injection or notice the needle hit resistance before full insertion, you may have reached muscle fascia — withdraw slightly and reposition at a shallower angle before injecting.
The abdomen provides 10–15% faster tesamorelin absorption than the anterior thigh due to higher subcutaneous blood flow in the periumbilical region. Phase 3 clinical trials demonstrating tesamorelin efficacy for VAT reduction used abdominal injection sites exclusively, making the abdomen the validated primary site. Thigh administration works as a secondary option when abdominal tissue is compromised or rotation capacity is exhausted, but abdominal sites should be prioritised whenever suitable tissue is available.
Lipohypertrophy is localised subcutaneous tissue thickening caused by repeated injections into the same site within a 4-week period. The condition results from chronic low-grade inflammation, collagen deposition, and adipocyte hypertrophy — creating palpable lumps or firmness under the skin. Lipohypertrophic tissue absorbs tesamorelin 20–30% less efficiently than healthy subcutaneous tissue, causing unpredictable pharmacokinetics even when dosing remains constant. Prevent lipohypertrophy through systematic site rotation with at least 7 days of recovery between repeat injections at any specific location.
Self-injection into the outer upper arm (posterior-lateral deltoid region) is technically possible but difficult due to limited visual access and awkward arm positioning required to reach the correct anatomical zone. Most patients require assistance from a caregiver or healthcare provider to inject into arm sites safely and consistently. The upper arm also offers the smallest usable surface area among FDA-approved subcutaneous injection zones, limiting rotation capacity to 4–5 discrete sites compared to 8+ sites available on the abdomen.
Apply gentle pressure with clean gauze or an alcohol pad for 30 seconds immediately after withdrawing the needle. Minor bleeding from capillary puncture during needle insertion is common and harmless — it doesn’t indicate incorrect technique or compromised injection efficacy. Skip that specific injection point for at least 10 days to allow complete healing before using it again in your rotation sequence. If bleeding is profuse, lasts longer than 2 minutes, or occurs frequently (more than once weekly), consult your prescribing physician.
Wait at least 7 days before injecting into the same subcutaneous location again. This recovery window allows inflammatory mediators to clear, microvascular trauma to heal, and tissue architecture to return to baseline before the next puncture. Using an 8-site rotation system on the abdomen — with each site spaced one inch apart — automatically builds in 7 days of recovery between repeat injections at any specific point when cycling through daily.
No — tesamorelin doesn’t directly target injection-site fat. It works by stimulating growth hormone secretion from the anterior pituitary gland, which then acts systemically on visceral adipose tissue (VAT) throughout the abdominal cavity via lipolytic signaling pathways. Injecting tesamorelin into the abdomen is recommended because that anatomical zone provides optimal subcutaneous tissue depth and absorption kinetics, not because proximity to VAT improves efficacy. The peptide’s therapeutic effect on visceral fat occurs regardless of injection site location once it enters systemic circulation.